Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Symmetry Investments LP bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,101 shares of the biotechnology company’s stock, valued at approximately $669,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Ensign Peak Advisors Inc grew its stake in shares of United Therapeutics by 27.2% in the second quarter. Ensign Peak Advisors Inc now owns 33,677 shares of the biotechnology company’s stock worth $10,728,000 after purchasing an additional 7,205 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in shares of United Therapeutics by 47.6% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 87,370 shares of the biotechnology company’s stock worth $27,832,000 after purchasing an additional 28,192 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the last quarter. Finally, Inspire Investing LLC grew its stake in shares of United Therapeutics by 40.3% in the second quarter. Inspire Investing LLC now owns 10,216 shares of the biotechnology company’s stock worth $3,254,000 after purchasing an additional 2,936 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $353.00 on Friday. The firm’s 50-day moving average price is $339.19 and its 200-day moving average price is $291.68. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The firm has a market capitalization of $15.66 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the prior year, the company posted $5.24 EPS. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now owns 5,107 shares in the company, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,922 shares of company stock worth $36,541,398. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Oppenheimer boosted their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. UBS Group boosted their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.